Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Neuer Top-Geologe an Bord - zündet jetzt die nächste Kursrakete?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
439 Leser
Artikel bewerten:
(2)

MMJ International Holdings: DEA's War on Marijuana Science: How Bureaucratic Clowns Are Blocking Clinical Trials While Spreading Fear Based Fiction

Duane Boise MMJ CEO opined "Now all eyes turn to DEA Administrator-nominee Terrance Cole. Thus far, his public marijuana statements have been evasive, his confirmation answers noncommittal, and his track record steeped in anti-cannabis fearmongering. However, as the DEA boss, he needs to stop the clown show in comparing cannabis to methamphetamine with no clinical basis and distributing memes claiming cannabis lowers sperm count by 50%, despite contradictory evidence".

WASHINGTON, DC / ACCESS Newswire / June 1, 2025 / The U.S. Drug Enforcement Administration (DEA) has once again embarrassed itself, this time by promoting the ludicrous claim that marijuana may cause more psychosis than methamphetamine. This sensationalist garbage-circulated through their "Just Think Twice" campaign-was framed with all the seriousness of a peer-reviewed journal, yet backed by none of the clinical evidence.

Let's be clear: this is not science. This is propaganda. And it's especially dangerous coming from the very agency actively obstructing legitimate, federally regulated research into the medical use of cannabis.

At the center of the absurdity is a cherry-picked quote from Oregon psychiatrist David Rettew, claiming that marijuana "raises the risk of psychotic disorders more than other drugs, even methamphetamines." There's no clinical study cited, no peer-reviewed data, no rigorous comparative analysis just an offhand opinion that the DEA spun into a headline to keep cannabis in the shadows.

Meanwhile, MMJ BioPharma Cultivation-one of the only companies in the country following federal law to the letter-is still barred from growing cannabis for FDA-authorized clinical trials.

Let that sink in.

The DEA refuses to let a federally compliant company conduct gold-standard scientific research, while simultaneously pushing psychobabble memes about marijuana and infertility, emojis that "mean drugs," and "natural highs" like pet stores and Instagram followers.

This is not a public health agency-it's a clown car with a badge.

MMJ BioPharma: The Victim of Bureaucratic Sabotage

MMJ BioPharma Cultivation has:

  • Two FDA-authorized INDs for treating Huntington's Disease and Multiple Sclerosis.

  • Orphan Drug Designation for its proprietary cannabinoid formulation.

  • A secure, DEA-inspected Schedule I analytical lab.

  • A state-of-the-art cultivation facility built to DEA specifications.

And yet, the DEA has refused for seven years to issue a Schedule I bulk manufacturing registration. Why? Not because of safety concerns. Not because of noncompliance. But because-unlike Curaleaf, Cookies, and other recreational giants-MMJ isn't playing the political lobbying game or hiding behind state loopholes. MMJ is doing it the right way, and that seems to be precisely the problem.

While cartels and corporate exporters freely move THC products overseas through "strategic partnerships" and shadowy legal gymnastics, MMJ is being crushed under the weight of federal inaction. The DEA has even subjected them to a constitutionally defective administrative hearing-overseen by an ALJ whose very authority the DOJ has now disavowed.

DEA: Champion of Pseudoscience and Policy Hypocrisy

Let's talk about the DEA's latest intellectual triumphs:

  • Comparing cannabis to methamphetamine with no clinical basis.

  • Telling teens to skip weed and chase Instagram fame instead.

  • Distributing memes claiming cannabis lowers sperm count by 50%, despite contradictory evidence.

  • Encouraging students to flood Instagram with "Anti-420" videos, weaponizing youth ignorance as public policy.

Meanwhile, the DEA continues to ignore the 2023 HHS recommendation to reschedule cannabis, based on real, peer-reviewed, FDA-analyzed scientific data.

You cannot claim to care about psychosis while blocking the very clinical trials designed to test safety, efficacy, and neurological effects. That's not science. That's obstruction.

Terrance Cole's Choice: Lead or Rubber Stamp the Marijuana Rot

Now all eyes turn to DEA Administrator-nominee Terrance Cole. Thus far, his public statements have been evasive, his confirmation answers noncommittal, and his track record steeped in anti-cannabis fearmongering.

If Cole refuses to address the unconstitutional DEA tribunals, if he refuses to approve MMJ's license after seven years of federal compliance, if he continues parroting outdated "gateway drug" nonsense-then the agency's credibility, already on life support, will collapse entirely.

End the Madness. Let Science Lead.

The DEA's current posture is untenable. It is promoting misinformation, blocking research, and enabling a regulatory regime that favors corporate exports and illicit markets while punishing pharmaceutical innovators.

MMJ BioPharma has done everything right. The DEA has done everything wrong.

It's time to stop the clown show, shut down the pseudoscience, and issue the damn license.

MMJ is represented by attorney Megan Sheehan.

CONTACT:
Madison Hisey
MHisey@mmjih.com
203-231-8583

SOURCE: MMJ International Holdings



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/deas-war-on-marijuana-science-how-bureaucratic-clowns-are-blocking-cl-1033504

© 2025 ACCESS Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.